These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20426547)

  • 1. ISHAGE GMP Workshop.
    Cytotherapy; 1999; 1(6):479. PubMed ID: 20426547
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimizing peripheral stem cell mobilization and harvest in very small children.
    Strahlendorf C
    J Clin Apher; 2005 Jul; 20(2):63-4. PubMed ID: 15892088
    [No Abstract]   [Full Text] [Related]  

  • 3. Creating Opportunities to Advance Stem Cell Science: 2019-2020 Year in Review.
    Srivastava D
    Stem Cell Reports; 2020 Jun; 14(6):993-995. PubMed ID: 32521249
    [No Abstract]   [Full Text] [Related]  

  • 4. US Food and Drug Administration international collaborations for cellular therapy product regulation.
    Arcidiacono JA; Blair JW; Benton KA
    Stem Cell Res Ther; 2012 Sep; 3(5):38. PubMed ID: 23021082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors that influence a mobilized HSC product.
    Nilsson SK
    Int J Hematol; 2017 Feb; 105(2):116-117. PubMed ID: 28013482
    [No Abstract]   [Full Text] [Related]  

  • 6. Donor selection and release criteria of cellular therapy products.
    Eichler H; Schrezenmeier H; Schallmoser K; Strunk D; Nystedt J; Kaartinen T; Korhonen M; Fleury-Cappellesso S; Sensebé L; Bönig H; Rebulla P; Giordano R; Lecchi L; Takanashi M; Watt SM; Austin EB; Guttridge M; McLaughlin LS; Panzer S; Reesink HW
    Vox Sang; 2013 Jan; 104(1):67-91. PubMed ID: 23252690
    [No Abstract]   [Full Text] [Related]  

  • 7. Enumeration of CD34-positive hematopoietic progenitor cells by flow cytometry: comparison of a volumetric assay and the ISHAGE gating strategy.
    Leuner S; Arland M; Kahl C; Jentsch-Ullrich K; Franke A; Höffkes HG
    Bone Marrow Transplant; 1998 Oct; 22(7):699-706. PubMed ID: 9818700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Legislative and ethical aspects of administering granulocyte colony-stimulating factor to normal donors.
    De Silvestro G; Marson P; Cesaro S; Messina C
    Haematologica; 2002 Aug; 87(8 Suppl):28-34. PubMed ID: 12412387
    [No Abstract]   [Full Text] [Related]  

  • 9. EBMT and ISHAGE-Europe create a foundation for inspection and accreditation in Europe.
    Kvalheim G; Berli M
    Cytotherapy; 1999; 1(5):363-4. PubMed ID: 20426536
    [No Abstract]   [Full Text] [Related]  

  • 10. Process validation.
    Preti RA
    Cytotherapy; 1999; 1(6):481-3. PubMed ID: 20426548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How we mobilize haemopoietic stem cells.
    Herbert KE; Levesque JP; Mills AK; Gottlieb DJ; Cooney J; Szer J; Rasko J; To LB
    Intern Med J; 2011 Aug; 41(8):588-94. PubMed ID: 21831119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mobilization of hematopoietic progenitor cells with a combination of docetaxel, adriamycin, 5-fluorouracil and filgrastim in breast cancer patients.
    Pérez-Calvo J; Fernández-Hidalgo O; Subirá ML; Martín-Algarra S; Salgado E; Brugarolas A
    Haematologica; 2001 Jan; 86(1):100-1. PubMed ID: 11146579
    [No Abstract]   [Full Text] [Related]  

  • 13. Fifth annual ISHAGE meeting - Oslo 1999.
    Brenner M
    Cytotherapy; 1999; 1(3):163. PubMed ID: 12881171
    [No Abstract]   [Full Text] [Related]  

  • 14. How do we mobilize and collect autologous peripheral blood stem cells?
    Yuan S; Wang S
    Transfusion; 2017 Jan; 57(1):13-23. PubMed ID: 27731496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [International approaches to the regulation of cell therapy products].
    Piatigorskaia NV; Tulina MA; Aladysheva ZhI; Beregovykh VV
    Vestn Ross Akad Med Nauk; 2013; (8):4-8. PubMed ID: 24340637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobilization with etoposide and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF.
    Scheid C; Reiser M; Draube A; Josting A; Fuchs M; Chemnitz J; Winter S; Schultz A; Engert A; Diehl V; Söhngen D
    J Hematother Stem Cell Res; 2000 Aug; 9(4):411-3. PubMed ID: 10982237
    [No Abstract]   [Full Text] [Related]  

  • 17. Cell processing practices in Argentina: report of a multicenter survey.
    Bertinetti C; Milone G; Kohan A; Saporito G; Robinson A; García JJ; Milone J; Cerutti I; Feldman L; Jarchum G; Bordone J; Koziner B
    Cytotherapy; 2001; 3(2):127-33. PubMed ID: 12028835
    [No Abstract]   [Full Text] [Related]  

  • 18. Hematopoietic progenitor cell count, but not immature platelet fraction value, predicts successful harvest of autologous peripheral blood stem cells.
    Mitani N; Yujiri T; Tanaka Y; Tanaka M; Fujii Y; Hinoda Y; Tanizawa Y
    J Clin Apher; 2011; 26(3):105-10. PubMed ID: 21647950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor.
    Lefrère F; Brignier AC; Elie C; Ribeil JA; Bernimoulin M; Aoun C; Dal Cortivo L; Delarue R; Hermine O; Cavazzana-Calvo M
    Adv Ther; 2011 Apr; 28(4):304-10. PubMed ID: 21400232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Peripheral blood stem cell transplantation--practices of mobilization and harvest].
    Sugio Y; Tokunaga Y; Nomura A; Inaba S
    Rinsho Byori; 1999 May; Suppl 110():63-9. PubMed ID: 10475033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.